Sarepta Therapeutics (SRPT)

[h2145h]

What does the smart money think about Sarepta Therapeutics Inc (NASDAQ:SRPT)?
At year's end, a total of 16 of the hedge funds we track were long in this stock, a change of 60% from one quarter earlier. With hedge funds' sentiment swirling, there exists a few key hedge fund managers who were increasing their holdings substantially. According to our comprehensive database, hedge fund perceptive advisors, managed by Joseph Edelman, holds the largest position in Sarepta Therapeutics Inc (NASDAQ:SRPT). Perceptive Advisors has a $33 million position in the stock, comprising 5.9% of its 13F portfolio. Sitting at the No. 2 spot is James E. Flynn of Deerfield Management, with a $19 million position; 1.1% of its 13F portfolio is allocated to the stock. Remaining peers that are bullish include Steven Cohen's SAC Capital Advisors, Phill Gross and Robert Atchinson's Capital Management 101 and Joseph Edelman's Perceptive Advisors 403.
As aggregate interest increased, key hedge funds have jumped into Sarepta Therapeutics Inc headfirst. Deerfield Management, managed by James E. Flynn, created the most valuable position in Sarepta Therapeutics Inc . Deerfield Management had 19 million invested in the company at the end of the quarter. Phill Gross and Robert Atchinson's hedge fund Adage Capital Management 101 also initiated a $10 million position during the quarter.